{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T07:08:20Z","timestamp":1743145700333,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":30,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071621141"},{"type":"electronic","value":"9781071621158"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":147,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although MRD monitoring by the classic polymerase chain reaction (PCR) approach is a powerful outcome predictor, about 20% of mantle cell lymphoma (MCL) and 50% of follicular lymphoma (FL) patients still lack a molecular marker and are thus resulting not eligible for MRD monitoring. Targeted locus amplification (TLA), a new NGS technology, has been revealed as a feasible marker screening approach able to identify uncommon B-cell leukemia\/lymphoma 1 (BCL1) and B-cell leukemia\/lymphoma 2 (BCL2) rearrangements in MCL and FL cases defined as having \u201cno marker\u201d by the classic PCR approach.<\/jats:p>","DOI":"10.1007\/978-1-0716-2115-8_8","type":"book-chapter","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T06:02:51Z","timestamp":1653631371000},"page":"119-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Locus Amplification as Marker Screening Approach to Detect Immunoglobulin (IG) Translocations in B-Cell Non-Hodgkin Lymphomas"],"prefix":"10.1007","author":[{"given":"Elisa","family":"Genuardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Alessandria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora Maria","family":"Civita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"key":"8_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375\u20132390","journal-title":"Blood"},{"key":"8_CR2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1038\/leu.2014.171","volume":"28","author":"M Dreyling","year":"2014","unstructured":"Dreyling M, Ferrero S, Hermine O (2014) How to manage mantle cell lymphoma. Leukemia 28:2117\u20132130","journal-title":"Leukemia"},{"key":"8_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ajh.23674","volume":"89","author":"A Freedman","year":"2014","unstructured":"Freedman A (2014) Follicular lymphoma: 2014 update on diagnosis and management. Am J Hematol 89:429\u2013436","journal-title":"Am J Hematol"},{"key":"8_CR4","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3324\/haematol.2017.167627","volume":"102","author":"S Ferrero","year":"2017","unstructured":"Ferrero S, Dreyling M (2017) Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach? Haematologica 102:1133\u20131136","journal-title":"Haematologica"},{"key":"8_CR5","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","volume":"115","author":"C Pott","year":"2010","unstructured":"Pott C, Hoster E, Delfau-Larue M-H, Beldjord K, B\u00f6ttcher S, Asnafi V et al (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115:3215\u20133223","journal-title":"Blood"},{"key":"8_CR6","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","volume":"122","author":"M Ladetto","year":"2013","unstructured":"Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E et al (2013) Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood 122:3759\u20133766","journal-title":"Blood"},{"key":"8_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11864-018-0594-1","volume":"19","author":"D Grimaldi","year":"2018","unstructured":"Grimaldi D, Genuardi E, Ferrante M, Ferrero S, Ladetto M (2018) Minimal residual disease in indolent lymphomas: a critical assessment. Curr Treat Options in Oncol 19:71","journal-title":"Curr Treat Options in Oncol"},{"key":"8_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-1-4939-9151-8_9","volume":"1956","author":"C Pott","year":"2019","unstructured":"Pott C, Br\u00fcggemann M, Ritgen M, van der Velden VHJ, van Dongen JJM, Kneba M (2019) MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods Mol Biol 1956:199\u2013228","journal-title":"Methods Mol Biol"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF03165276","volume":"76","author":"M Seto","year":"2002","unstructured":"Seto M (2002) Molecular mechanisms of lymphomagenesis through transcriptional disregulation by chromosome translocation. Int J Hematol 76:323\u2013326","journal-title":"Int J Hematol"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41375-019-0559-9","volume":"34","author":"C Pott","year":"2020","unstructured":"Pott C, Sehn LH, Belada D, Gribben J, Hoster E, Kahl B et al (2020) MRD response in relapsed\/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. Leukemia 34:522\u2013532","journal-title":"Leukemia"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VHJ van der Velden","year":"2007","unstructured":"van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al (2007) Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604\u2013611","journal-title":"Leukemia"},{"key":"8_CR12","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJM van Dongen","year":"2003","unstructured":"van Dongen JJM, Langerak AW, Br\u00fcggemann M, Evans PAS, Hummel M, Lavender FL et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257\u20132317","journal-title":"Leukemia"},{"key":"8_CR13","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1182\/blood.V95.8.2651","volume":"95","author":"JW Donovan","year":"2000","unstructured":"Donovan JW, Ladetto M, Zou G, Neuberg D, Poor C, Bowers D et al (2000) Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood 95:2651\u20132658","journal-title":"Blood"},{"key":"8_CR14","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","volume":"120","author":"M Faham","year":"2012","unstructured":"Faham M, Zheng J, Moorhead M, Carlton VEH, Stow P, Coustan-Smith E et al (2012) Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 120:5173\u20135180","journal-title":"Blood"},{"key":"8_CR15","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/s41375-019-0496-7","volume":"33","author":"M Br\u00fcggemann","year":"2019","unstructured":"Br\u00fcggemann M, Kotrov\u00e1 M, Knecht H, Bartram J, Boudjogrha M, Bystry V et al (2019) Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia 33:2241\u20132253","journal-title":"Leukemia"},{"key":"8_CR16","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.1182\/blood-2019-124645","volume":"134","author":"S Oliva","year":"2019","unstructured":"Oliva S, Genuardi E, Belotti A, Frascione PMM, Galli M, Capra A et al (2019) Minimal residual disease evaluation by multiparameter flow cytometry and next generation sequencing in the forte trial for newly diagnosed multiple myeloma patients. Blood 134:4322","journal-title":"Blood"},{"key":"8_CR17","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","volume":"123","author":"J Martinez-Lopez","year":"2014","unstructured":"Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonz\u00e1lez M, Barrio S, Ayala R et al (2014) Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123:3073\u20133079","journal-title":"Blood"},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2013.375","volume":"28","author":"M Ladetto","year":"2014","unstructured":"Ladetto M, Br\u00fcggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D et al (2014) Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 28:1299\u20131307","journal-title":"Leukemia"},{"key":"8_CR19","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","volume":"125","author":"DM Kurtz","year":"2015","unstructured":"Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA et al (2015) Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 125:3679\u20133687","journal-title":"Blood"},{"key":"8_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3324\/haematol.2016.155424","volume":"102","author":"D Wren","year":"2017","unstructured":"Wren D, Walker BA, Br\u00fcggemann M, Catherwood MA, Pott C, Stamatopoulos K et al (2017) Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing. Haematologica 102:57\u201360","journal-title":"Haematologica"},{"key":"8_CR21","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2019-127822","volume":"134","author":"P Stewart","year":"2019","unstructured":"Stewart P, Gazdova J, Darzentas N, Wren D, Proszek P, Fazio G et al (2019) Euroclonality-NGS DNA capture panel for integrated analysis of IG\/TR rearrangements, translocations, copy number and sequence variation in lymphoproliferative disorders. Blood 134:888","journal-title":"Blood"},{"key":"8_CR22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/nbt.2959","volume":"32","author":"PJP de Vree","year":"2014","unstructured":"de Vree PJP, de Wit E, Yilmaz M, van de Heijning M, Klous P, Verstegen MJAM et al (2014) Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping. Nat Biotechnol 32:1019\u20131025","journal-title":"Nat Biotechnol"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-1-4939-6442-0_13","volume":"1492","author":"QP Hottentot","year":"2017","unstructured":"Hottentot QP, van Min M, Splinter E, White SJ (2017) Targeted locus amplification and next-generation sequencing. Methods Mol Biol 1492:185\u2013196","journal-title":"Methods Mol Biol"},{"key":"8_CR24","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1038\/s41467-019-12412-1","volume":"10","author":"I Godet","year":"2019","unstructured":"Godet I, Shin YJ, Ju JA, Ye IC, Wang G, Gilkes DM (2019) Fate-mapping post-hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis. Nat Commun 10:4862","journal-title":"Nat Commun"},{"key":"8_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omtm.2020.08.011","volume":"19","author":"YH Chen","year":"2020","unstructured":"Chen YH, Pallant C, Sampson CJ, Boiti A, Johnson S, Brazauskas P et al (2020) Rapid lentiviral vector producer cell line generation using a single DNA construct. Mol Ther Method Clin Dev 19:47\u201357","journal-title":"Mol Ther Method Clin Dev"},{"key":"8_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201800371","volume":"14","author":"SH Aeschlimann","year":"2019","unstructured":"Aeschlimann SH, Graf C, Mayilo D, Lindecker H, Urda L, Kappes N et al (2019) Enhanced CHO clone screening: application of targeted locus amplification and next-generation sequencing technologies for cell line development. Biotechnol J 14:e1800371","journal-title":"Biotechnol J"},{"key":"8_CR27","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1373\/clinchem.2017.286047","volume":"64","author":"MZ Alimohamed","year":"2018","unstructured":"Alimohamed MZ, Johansson LF, De Boer EN, Splinter E, Klous P, Yilmaz M et al (2018) Genetic screening test to detect translocations in acute leukemias by use of targeted locus amplification. Clin Chem 64:1096\u20131103","journal-title":"Clin Chem"},{"key":"8_CR28","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1182\/blood-2015-05-644039","volume":"126","author":"R Kuiper","year":"2015","unstructured":"Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, el Jarari L et al (2015) Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood 126:1996\u20132004","journal-title":"Blood"},{"issue":"3","key":"8_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/hon.2864","volume":"39","author":"E Genuardi","year":"2021","unstructured":"Genuardi E, Klous P, Mantoan B, Drandi D, Ferrante M, Cavallo F et al (2021) Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. Hematol Oncol 39(3):293\u2013303","journal-title":"Hematol Oncol"},{"key":"8_CR30","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1073\/pnas.88.12.5413","volume":"88","author":"G Gaidano","year":"1991","unstructured":"Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW et al (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci 88:5413\u20135417","journal-title":"Proc Natl Acad Sci"}],"container-title":["Methods in Molecular Biology","Immunogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2115-8_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T06:03:13Z","timestamp":1653631393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2115-8_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9781071621141","9781071621158"],"references-count":30,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2115-8_8","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"28 May 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}